This is the intelligence company's fifth acquisition.
CorEvitas announced the acquisition of Pregistry LLC, a company focused on safety studies during pregnancy.
Pregistry utilizes 70 pregnancy experts to provide reports and studies on healthy pregnancies and births. The group collects data based on clinical, safety, regulatory, marketing, and technology needs and is then shared with individuals, providers, and industry stakeholders. This information is reportedly used by doctors as part of their decisions on what medications and vaccines to prescribe.
In a press release, Dr. Diego Wysznski, founder and chief executive officer of Pregistry, said, “For the last eight years, Pregistry has been a leader in the design and execution of pregnancy exposure registries to fulfill global regulatory commitments, such as mandates from the FDA and the EMA, and other observational studies in the maternal health field, including the world's largest pregnancy registries on COVID-19 vaccines and Covid treatments.”
CorEvitas is an intelligence company to provides a syndicated network of registries. Pregistry is its fifth acquisition.
Continue reading this story here.
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.